Sicart Associates LLC Buys Shares of 6,981 Regeneron Pharmaceuticals, Inc. $REGN

by · The Markets Daily

Sicart Associates LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,981 shares of the biopharmaceutical company’s stock, valued at approximately $3,925,000.

Several other institutional investors have also recently made changes to their positions in REGN. Union Bancaire Privee UBP SA grew its position in Regeneron Pharmaceuticals by 10,440.0% during the third quarter. Union Bancaire Privee UBP SA now owns 517 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 522 shares during the period. Moody National Bank Trust Division boosted its stake in shares of Regeneron Pharmaceuticals by 19.2% during the 3rd quarter. Moody National Bank Trust Division now owns 1,786 shares of the biopharmaceutical company’s stock worth $1,004,000 after acquiring an additional 288 shares during the last quarter. Heartwood Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $133,000. Insight Wealth Strategies LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $4,092,000. Finally, Aaron Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $449,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on REGN shares. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Canaccord Genuity Group raised their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Scotiabank boosted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Finally, Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $779.45.

Read Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $746.36 on Wednesday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $790.98. The stock has a 50-day moving average price of $671.04 and a 200 day moving average price of $595.57. The stock has a market capitalization of $78.44 billion, a P/E ratio of 17.87, a P/E/G ratio of 2.15 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the firm earned $12.46 EPS. The firm’s revenue was up .9% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).